Podcast terbaik Talking Oncology (2024)

1
04_10 Testicular Cancer II 25:59

18d ago25:59

25:59

1. Stage II Disease 2. Overview of BEP, EP, VIP 3. Advanced, refractory disease 4. Survivorship considerations Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to y…

1
Advanced Melanoma: CheckMate 067 10-Year Data Show Prognoses Transformed By Checkpoint Inhibitors 14:28

14d ago14:28

14:28

Sustained responses and long-term overall survival have resulted from checkpoint inhibitor therapy for advanced melanoma, transforming the prognosis for as many as half of patients. This is according to 10-year survival outcomes from the Phase Ill CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma that were reported at the ESMO C…

1
Preoperative Chemoradiation Ruled Out for Gastric or GE Junction Resectable Adenocarcinoma 8:07

14d ago8:07

8:07

The addition of preoperative chemoradiation therapy to perioperative chemotherapy did not improve overall survival as compared with perioperative chemotherapy alone in patients with resectable gastric or gastroesophageal junction adenocarcinomas. The multi-continent, Phase III randomized TOPGEAR trial has definitively found no benefit from adding r…

1
Perioperative Checkpoint Inhibition Better for Muscle-Invasive Bladder Cancer 9:00

14d ago9:00

9:00

Patients with muscle-invasive bladder cancer experienced “clinically meaningful” improvements in key outcomes—event-free survival and overall survival—when the immune checkpoint inhibitor durvalumab was added to their standard neoadjuvant chemotherapy.This was in research findings, reported at the ESMO Congress 2024, from the NIAGARA randomized Pha…

1
Recurrent Glioma: Encouraging Responses to Autologous Myeloid Dendritic Cell Therapy 10:45

14d ago10:45

10:45

When patients with recurrent high-grade glioblastoma were treated with autologous myeloid dendritic cells, they had clinical responses described as “encouraging” in a Phase I clinical trial reported at the ESMO Congress 2024.Cells harvested from each patient were injected directly into the resection cavity brain tissue lining after surgery. Patient…

1
A Playlist for Breast Cancer Stories | EP 61 16:00

17d ago16:00

16:00

In this episode, I've curated a special playlist of podcast episodes for Breast Cancer Awareness Month. I believe that sharing stories and experiences can provide emotional support and inspiration for individuals battling breast cancer. We'll discuss the significance of certain stories, and how listening to others' experiences can help people cope …

1
Therapeutic mRNA Vaccine Brings New Hope in Glioblastoma 12:05

21d ago12:05

12:05

Patients with newly diagnosed, surgically resected MGMT-unmethylated glioblastoma may benefit from treatment with a therapeutic mRNA vaccine called CVGBM, according to findings from a first-in-human, Phase I safety and dose-escalation study from Tübingen, Germany, reported at the ESMO Congress 2024 held in Barcelona. The CVGBM vaccine encodes multi…

1
Resectable Stage III Melanoma: Unprecedented Survival Benefit With Pure Checkpoint Inhibitor Neoadjuvant Therapy 6:17

21d ago6:17

6:17

A large, expanded-cohort pooled analysis of neoadjuvant immunotherapy for patients with resectable Stage III melanoma has reported very high rates of durable survival. The findings from the world’s biggest center of expertise in melanoma were announced at ESMO Congress 2024. The study included patients from clinical trials and real-world studies wh…

1
Circulating Tumor DNA Directs Precision Management for Ovarian Cancer 10:01

29d ago10:01

10:01

Drug resistance can be delayed and treatment outcomes predicted in patients with ovarian cancer with the help of relatively low-cost molecular precision management techniques using liquid biopsies. These are being developed by a team at the University of California in Los Angeles (UCLA) led by Jian Yu Rao, MD, Vice Chair of Diagnostic Technology In…

1
ESMO Reports Neoadjuvant Therapy for TNBC, Combination Checkpoint Inhibition, Artificial Intelligence & More 13:23

1M ago13:23

13:23

Important findings about the benefit of neoadjuvant therapies, especially those involving checkpoint inhibition, have been reported at the ESMO 2024 Congress. Rebecca Dent, MD, Scientific Chair of the meeting, as well as Medical Oncologist and Deputy Chief Executive Officer at the National Cancer Center in Singapore (with a special interest in all …

1
Cardio-Oncology: Many Cancer Treatment Cardiotoxicities Still to Be Understood 13:04

1M ago13:04

13:04

The escalating danger of cardiac toxicity posed by a range of increasingly effective anti-cancer therapies is insufficiently understood, according to the head of a world center of excellence for the study of cardio-oncology in northern China. At a special session devoted to cardio-oncology held at the Chinese Society of Clinical Oncology (CSCO) 202…

1
Emerging Potential for Cell Therapies in Ovarian Cancer and Other Solid Tumors 9:51

1M ago9:51

9:51

Details of the expanding range of cell therapies beyond hematologic malignancy were reported at the 2024 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) by Oliver Dorigo, MD, PhD, Director of the Division of Gynecologic Oncology at the Stanford Women's Cancer Center in Stanford University. After his talk at CSCO, Dorigo told Oncol…

1
Global Cooperation on Antibody-Drug Conjugates: Key Driver of Progress in HER2-Dependent Metastatic Breast Cancer Treatment 8:43

1M ago8:43

8:43

An assessment of progress with antibody-drug conjugates (ADCs) for the treatment of HER2-dependent metastatic breast cancer was given at the 2024 Chinese Society of Clinical Oncology (CSCO) Annual Meeting. The President-Elect of the European Society for Medical Oncology (ESMO), Giuseppe Curigliano, MD, PhD, Director of the Early Drug Development fo…

1
World-Wide Clinical Perspectives from Chinese Society of Clinical Oncology’s Globally Upscale 2024 Annual Meeting 8:21

1M ago8:21

8:21

At the opening session of the Chinese Society of Clinical Oncology (CSCO) 2024 Annual Meeting, attended by nearly 30,000 cancer specialists, Oncology Times reporter Peter Goodwin asked the President of CSCO, Xu Ruihua, MD, PhD, Professor and President of Sun Yat-sen University Cancer Center in Guangzhou, China, to talk about some of the ways that p…

1
Breastfeeding is Safe After Treatment for BRCA-Positive Breast Cancer 7:26

1M ago7:26

7:26

Important findings about the benefit of neoadjuvant therapies, especially those involving checkpoint inhibition, have been reported at the 2024 Annual meeting of the European Society for Medical Oncology, ESMO. The Scientific Chair of the meeting, Rebecca Dent MD, Deputy Chief Executive Officer of the National Cancer Center in Singapore, told Oncol…

1
Breastfeeding After Hormone Receptor-Positive Breast Cancer: No Detectable Risk for Patients 11:33

2M ago11:33

11:33

Women who chose to interrupt their endocrine therapy after their breast cancer surgery to have a baby faced no additional cancer risk, according to data from the POSITIVE study reported at the ESMO Congress 2024. In Barcelona, OncTimesTalk reporter Peter Goodwin met up with Fedro Peccatori, MD, PhD, Director of the Fertility and Procreation Unit in…

1
Findings at ESMO 2024 Highlighting the Benefit of Neoadjuvant Therapies 13:23

2M ago13:23

13:23

Important findings about the benefit of neoadjuvant therapies, especially those involving checkpoint inhibition, have been reported at the ESMO 2024 Congress. Rebecca Dent MD, Scientific Chair of the meeting, as well as Medical Oncologist and Deputy Chief Executive Officer at the National Cancer Center, Singapore (with a special interest in all asp…

1
04_09 Testicular Cancer I 28:18

2M ago28:18

28:18

1. Background, work up 2. Staging of seminoma and NSGCT 3. Young Adult/Adolescent Oncology 4. Management of Stage I Disease Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizatio…

1
From Diagnosis to Defiance: Michelle Patidar's Cancer Survival Story | EP 60 44:52

2M ago44:52

44:52

In this conversation, we sit down with Michelle Patidar from Chicago, , a cancer survivor, integrative nutrition health consultant, and founder of Revival Health & Wellness. Michelle shares her personal journey with Non-Hodgkin's lymphoma and how her experience led her to create a space for others to heal from the inside out. We'll discuss her holi…

1
From Losing a Husband to Saving Her Son: Michael and Ashlee Cramer's Cancer Journey | EP 59 55:06

3M ago55:06

55:06

In this conversation, we sit down with Michael and Ashlee Cramer, a mother and son from Florida who faced unimaginable challenges. Michael, diagnosed with rare Hepatosplenic T-cell lymphoma at 19, defied the odds with the support of his mother, Ashlee, who became his full-time caregiver. Together, they endured intense treatments and a recent battle…

1
Stronger Together: Advancing Native American Cancer Health Equity 1:01:18

3M ago1:01:18

1:01:18

Join us as we spotlight the groundbreaking efforts of the Center for Native American Cancer Health Equity (C-NACHE) in addressing Native American cancer health inequities. Through insightful interviews, we explore the challenges Native communities face when seeking cancer care and the center's initiatives in broadening awareness and amplifying comm…

1
Cooking Up a Cure with Chloë Crampton | EP 58 42:12

3M ago42:12

42:12

In this episode, we sit down with Chloë Crampton from London, England, UK, a former actress turned chef and nutrition coach. Chloë bravely shares her personal battle with triple-negative breast cancer, offering hope and inspiration to others facing similar challenges. Discover how she transformed her life after her diagnosis, focusing on healing th…

1
04_08 Metastatic Renal Cell Carcinoma 24:16

3M ago24:16

24:16

1. Historical Approach (cytoreduction, IFN-a, sunitinib 2. Prognostic risk scores 3. Evidence for modern doublet regimens 4. Later line therapy Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO a…

1
Battling Follicular Lymphoma with Resilience and Hope with Susete Ferreira | EP 57 56:55

4M ago56:55

56:55

In this episode, we speak with Susete Ferreira, a Toronto-based cancer warrior originally from Portugal. Susete shares her incredible journey from initially mistaking cancer symptoms for menopause to being diagnosed with stage 4 follicular lymphoma, a type of blood cancer. Despite the intense pain and challenges, Susete's positivity and resilience …

1
HPV Vaccination Prevents HIV-Related Cancers in Men 6:02

4M ago6:02

6:02

HPV vaccination for girls and boys in the United States has led to a real-world reduction of oral head and neck cancers in men, as well as the already documented prevention of cervical cancers in women, even though uptake of the vaccine in the U.S. has been suboptimal. This is according to findings from a retrospective analysis of HPV-associated ca…

1
Proton Pump Inhibitors Bigger Impact on Dasatinib Efficacy in CML Than Previously Thought 4:31

4M ago4:31

4:31

Although co-medication with proton pump inhibitors (PPI) is not advised for patients being treated with dasatanib for their chronic myeloid leukemia (CML), confirmation that this recommendation is often overlooked has been reported in a study led by Torsten Dahlén, a PhD student at the Karolinska Institutet in Stockholm, Sweden. Furthermore, the st…

1
Immune-Related Adverse Events Predict Response to Checkpoint Inhibitor Monotherapy in Advanced Head & Neck Cancers 6:28

4M ago6:28

6:28

Patients who had immune-related adverse events had better responses and lived longer than those who didn’t. This was a real-world observational study of patients with recurrent or metastatic head and neck squamous cell carcinoma treated with immune checkpoint inhibitor monotherapy, reported at the 2024 ASCO Annual Meeting.OncTimesTalk reporter Pete…

1
A Multi-Drug Algorithm Used to Accurately Predict Best First-Line Treatments in Patients With Newly Diagnosed Acute Myeloid Leukemia 7:39

4M ago7:39

7:39

A mathematical model using data from routine diagnostic samples has been found to accurately predict individual patient responses to the main candidate first-line treatments for acute myeloid leukemia. Findings from a validation study in independent patient cohorts led by researchers from the Barts Cancer Institute at the Queen Mary University of L…

1
04_07 Localized Renal Cell Carcinoma 25:15

4M ago25:15

25:15

1. Risk Factors and Presentation 2. Staging and Paraneoplastic syndromes 3. Localized Therapy Options and Considerations 4. Evidence and Limitations for Adjuvant Systemic Therapy Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of g…

1
MUC-1 Vaccine Delays Breast Cancer Distant Recurrence & Extends Survival 9:02

5M ago9:02

9:02

When the mucin-1 (MUC-1) vaccine tecemotide was added to standard-of-care neoadjuvant systemic therapy, investigators in Austria found improved long-term outcomes in women with early breast cancer. Individuals vaccinated with tecemotide had markedly longer distant recurrence-free and overall survival. This was in the randomized prospective ABCSG-34…

1
Telehealth Triumphs for Palliative Care Delivery in Patients With Lung Cancer 14:15

5M ago14:15

14:15

Not only can palliative care be delivered effectively by telehealth to patients with advanced non-small cell lung cancer, it’s also as effective as face-to-face delivery by specialist clinicians, according to a study reported at the 2024 ASCO Annual Meeting. In addition, telehealth turned out to be more popular. For the Oncology Times podcast, OncT…

1
Lymphadenectomy Can Be Safely Omitted for Patients With Advanced Epithelial Ovarian Cancer Lacking Suspicious Lymph Nodes 10:53

5M ago10:53

10:53

The CARACO prospective, multi-institutional, Phase III trial, among patients with newly diagnosed advanced epithelial ovarian cancer, found that lymphadenectomy should be omitted in patients with clinically negative lymph nodes, as well as those undergoing neoadjuvant chemotherapy and interval complete surgery. This finding from the University of N…

1
Neoadjuvant Checkpoint Inhibitor Combination Beats Standard Surgery With Adjuvant Immunotherapy in Macroscopic, Resectable Stage III Melanoma 11:34

5M ago11:34

11:34

A combination of two checkpoint inhibitors used as neoadjuvant therapy for macroscopic, resectable Stage III melanoma brought a highly statistically significant improvement over the standard of care: surgery followed by checkpoint inhibition (therapeutic lymph node dissection followed by adjuvant therapy with nivolumab, pembrolizumab or, in BRAFmut…

1
Healing Through Nutrition with Alison Tierney | EP 56 58:15

5M ago58:15

58:15

In this episode, we sit down with Alison Tierney, a Milwaukee, Wisconsin-based cancer nutritionist specialist. Alison shares her powerful journey from battling infertility and PCOS to being diagnosed with breast cancer at 33. Despite facing these challenges, she embraced a plant-based diet that transformed her life. Alison discusses how food can be…

1
Asciminib May Be a Safer, More Effective Treatment for Patients With Newly Diagnosed Chronic Myeloid Leukemia 9:25

5M ago9:25

9:25

Primary results from ASC4FIRST trial, the first study in chronic myeloid leukemia comparing current standard-of-care frontline tyrosine kinase inhibitors with the novel agent asciminib in newly diagnosed patients, were reported at the 2024 ASCO Annual Meeting. First author Timothy Hughes MD, Consultant Hematologist with the Royal Adelaide Hospital,…

1
Chemotherapy Before and After Surgery Improved Outcomes for Patients With Resectable Locally Advanced Esophageal Adenocarcinoma 6:52

5M ago6:52

6:52

Treatment with perioperative chemotherapy, with chemotherapy before and after surgery, brought superior outcomes for patients with locally advanced esophageal adenocarcinoma, in research reported to the 2024 ASCO Annual Meeting. Lead author Jens Höppner FAChirg, FACS, MD, Director of the Department of Surgery in the University Medical Center at the…

1
Trastuzumab Deruxtecan Delays Progression in HR+, HER2-low, and HER2 Ultralow Breast Cancer After Endocrine Therapy 8:13

5M ago8:13

8:13

Data from the DESTINY Breast06 trial using the antibody-drug conjugate trastuzumab deruxtecan to treat patients with estrogen receptor positive (HR+), human epidermal growth factor receptor-low (HER2-low), and HER2-ultralow breast cancer after endocrine therapy, show longer progression-free survival in comparison with standard chemotherapy. After a…

1
Study Supports Osimertinib as Standard of Care for Patients With Locally Advanced EGFR-Mutated NSCLC 8:50

5M ago8:50

8:50

New data from the Phase III LAURA study, reported in Chicago at the ASCO 2024 Annual Meeting Plenary Session, suggest that the tyrosine kinase inhibitor osimertinib could become standard of care for treating patients whose unresectable locally advanced lung cancers test positive for mutated epidermal growth factor receptor (EGFR) and have no progre…

1
Study Finds Durvalumab Improved Progression-Free and Overall Survival in Limited Stage Small Cell Lung Cancer 11:34

5M ago11:34

11:34

When the immune checkpoint inhibitor durvalumab was added to standard-of-care chemoradiation treatment for patients with limited-stage small-cell lung cancer, it brought a “statistically significant and clinically meaningful” improvement in overall and progression-free survival, compared to adding placebo. This was in data from the ADRIATIC study r…

1
German Study Finds New Regimen for Hodgkin Lymphoma More Effective, Less Toxic 17:36

5M ago17:36

17:36

An improvement over standard care in both efficacy and safety of a new combination regimen for treating Hodgkin lymphoma was discussed at the 2024 ASCO Annual Meeting in Chicago. The six-drug BrECADD regimen was compared with the high-achieving German-originated BEACOPP chemotherapy that has been widely adopted as standard of care. During the confe…

1
Persevering Through A Rare Blood Cancer with Harjeet Kaur | EP 55 50:17

5M ago50:17

50:17

In this inspiring episode, we welcome Harjeet Kaur, a remarkable individual who migrated from India to Canada and faced a rare form of blood cancer. Harjeet shares her powerful journey of diagnosis, treatment, and resilience, offering invaluable insights into her battle with this challenging disease. She opens up about the emotional and physical hu…

1
Best Gems & Highlights of 2023: Part 2 | EP 54 23:50

5M ago23:50

23:50

In Part Two of our series, we dive deeper into the inspiring journeys and insights of cancer patients and survivors from 2023. We highlight their resilience, courage, and triumphs in the face of adversity, celebrating their enduring legacies and the progress made in the fight against cancer. Tune in for heartfelt interviews and moving stories that …

1
Kinase Inhibitor Delivers Synthetic Lethality to Enhance Radiotherapy in Glioblastoma 10:31

6M ago10:31

10:31

The 2024 AACR Annual Meeting heard that an “efficacy signal” was detected in an international Phase I study of a new radiosensitizer, tested as adjunctive therapy (combined with standard radiation plus temozolomide) in patients with recurrent glioblastoma. After reporting his group’s early findings of AZD1390, an inhibitor of ataxia telangiectasia …

1
mRNA Vaccine + Checkpoint Inhibitor Combo Had Low Toxicity With Evidence of Efficacy in Advanced NSCLC 8:21

6M ago8:21

8:21

A combination of a new mRNA vaccine used together with a programmed death-ligand 1 (PD-L1) immune checkpoint inhibitor to treat patients with lung cancer was markedly less toxic than a combination of the same vaccine with chemotherapy. However, it was apparently just effective. This is according to findings from a study reported to the 2024 AACR An…

1
Earliest Detection of Cancer by Artificial Intelligence Analysis of Circulating Cell-Free DNA Fragmentomes 13:46

6M ago13:46

13:46

A new blood test that uses artificial intelligence to analyze circulating molecular markers for the earliest signs of ovarian and other cancers has been reported by researchers. At the AACR 2024 Annual Meeting in San Diego, Victor Velculescu, MD, PhD, Co-Director of the Cancer Genetics & Epigenetics Program at Johns Hopkins Kimmel Cancer Center, re…

1
04_06 Metastatic Urothelial Cancer 24:33

6M ago24:33

24:33

1. Immunohistochemistry of urothelial cancer 2. History of systemic therapy in advanced and metastatic disease 3. Pembrolizumab and Enfortumab Vedotin 4. Approach to second line therapy and beyond Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly enc…

1
Clinical Study Shows Selective PARP 1 Inhibitor More Effective, Less Toxic 17:35

6M ago17:35

17:35

An early study using selective inhibition of the Poly (ADP-ribose) polymerase (PARP) has provided evidence it could bring greater cancer control with less toxicity than the well-proven non-selective PARP 1 and PARP 2 inhibitors already in use for treating a number of tumor types. At the AACR Annual Meeting 2024, Timothy Yap, PhD, MD, MBBS, Vice Pre…

1
Exercise Deters Prostate Cancer Death & Progression 10:24

6M ago10:24

10:24

Findings from a new study support a body of evidence showing that physical exercise can bring benefits to patients with advanced prostate cancer. Data from an intervention study reported at the AACR Annual Meeting 2024 are consistent with mounting epidemiological evidence showing that regular physical exercise can help patients with advanced or met…

1
Bispecific Dual Checkpoint Blockade Extends Life & Slows Progression in Gastric & GE Junction Cancers 9:31

6M ago9:31

9:31

Double checkpoint blockade using a single bispecific agent could become the new standard for treating advanced gastric cancer regardless of PD-L1 status, according to research reported at the AACR Annual Meeting 2024. The investigational bispecific antibody drug cadonilimab (used with chemotherapy) significantly extended life and delayed disease pr…

Podcast Berbaloi untuk Didengar

Podcast Talking Oncology

Podcast Berbaloi untuk Didengar

Panduan Rujukan Pantas